Head & Neck Cancer

In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.

To date, there is still no strong evidence that induction chemotherapy improves outcomes for locally advanced head and neck cancer.

Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.

Researchers at Boston University School of Medicine have identified a marker that can detect carcinoma-associated fibroblasts (CAFS) in oral cancer tissues.

Dental exams and procedures should occur before treatment begins for patients with head and neck cancer and other malignancies, and post-treatment dental follow-up care should be life-long for cancer survivors.

In this interview, we speak with Dr. Robert Ferris about the results from the CheckMate-141 study, which investigated the efficacy of nivolumab in head and neck cancer.

Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.

Undergoing surveillance with PET/CT resulted in similar survival to planned neck dissection in patients with squamous cell carcinoma of the head and neck with nodal disease who have completed chemoradiotherapy.

The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.

Compared to the general population, the rate of suicide is three times more frequent among head and neck cancer patients, according to a retrospective study.

This article reviews the pathology and current evidence on systemic therapies for the management of advanced salivary gland cancers that are not amenable to local therapy.

The diversity and complexity, combined with the rarity of salivary gland malignancies, lead to definite and distinct challenges in their study, and consequently in advancing treatment options for affected patients.

Undergoing primary surgery may be the best treatment option for patients with advanced oropharyngeal and hypopharyngeal cancers.

Pretreatment depression was linked with poorer nutritional and survival outcomes among newly diagnosed patients with head and neck squamous cell carcinoma.

By introducing a patient-centric navigation system, researchers were able to provide treatment recommendations to the majority of patients with head and neck cancer within a 2-week period.

This review discusses current paradigms in the diagnosis and management of HPV-OPSCC, and we emphasize pertinent research questions to investigate going forward, including whether to deintensify treatment in these patients.

Although screening methods for HPV-OPSCC have not yet been developed, population-based prevention may be achievable through HPV vaccination, but only if concerted efforts are made to increase vaccine uptake in the United States.

A new study found that in patients treated for oropharyngeal cancer, the detection of HPV16 DNA via an oral rinse could be a sign of poor prognosis.

Detection of antibodies against HPV16 in the blood of patients with HPV-positive oropharyngeal carcinoma correlates with improved survival.

Elective neck lymph node surgery for patients with early oral cancer reduces the risk of cancer recurrence and improves survival.

Pembrolizumab demonstrated a 24.8% overall response rate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

A new study found that compliance with post-treatment clinical surveillance improved survival outcomes in patients with head and neck squamous cell carcinoma.

A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.

The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV.

Vaccinating boys aged 12 years against the human papillomavirus (HPV) may be cost-effective in the prevention of oropharyngeal cancer.

The FDA has approved lenvatinib (Lenvima) for the treatment of patients with progressive, differentiated thyroid cancer refractory to radioactive iodine.

An infection with oral HPV16 is likely to last for a year or longer in older men, putting them at higher risk for the development oropharyngeal cancer.

Cancer survivors are at an increased risk for developing a second smoking-associated cancer if they smoked cigarettes prior to their first cancer diagnosis.

Using tobacco is linked to an increased risk of infection with oral HPV type 16, a sexually transmitted virus known to cause cancers of the mouth and throat.

In patients with recurrent or metastatic head and neck squamous cell carcinoma, afatinib better delayed cancer progression compared with methotrexate, according to results presented at the 2014 ESMO Congress.